Small Molecule API (Active Pharmaceutical Ingredients) Market Top Trends, Growth, Major Drivers, Top 10 Players, Size, Revenue and Forecast to 2023

“Small Molecule API Market”
MRFR Provides Appropriate Analysis of Global Small Molecule API Market Geographical Analysis, Scope, Applications, Products, Prominent Audience, End Users, and Market Players for Global, and Country Level Market Segments, etc

Global Small Molecule API Market will reach approximately 279.7 BN USD by 2027, registering 7% CAGR throughout the estimated period (2016 – 2027).

Small molecule active pharmaceutical ingredient or Small molecule is a low weight (< 900 daltons) organic compound used as an API in the biology and pharmacology to regulate a biological process. Most of the drugs are small molecules except larger structures such as nucleic acids and proteins and polysaccharides.

Small molecule APIs are an important and highly effective component of the bio/pharmaceutical portfolio Seamlessly using small molecule API ensures speeding the drug development process and early phase trials, further allowing the faster commercial success.

Most of the important drugs introduced in recent years, including kinase inhibitors like Gleevec and anti-retroviral products like Sovaldi, are small molecule APIs. Despite the emergence of biologics, small-molecule APIs are garnering a huge market prominence owing to the considerable advantages it offers over large molecules.

Request Sample Copy at

As a result, Small molecule API account for a larger amount of application in new drug discovery and new molecular entities. There can be no doubt that the number and share of small molecule API are increasing and consequently, its market size is increasing on the global platform.

Additional factors, positively impacting the market growth include the rise in demand for the small molecule drugs, development in the infrastructure in the pharmaceutical industry, and the entry of big CDMO’s into the business. Furthermore, rising access to the quality healthcare and medication in the developing and underdeveloped countries fosters the market growth of the small molecule API.

Conversely, factors such as the increasing complexities in the clinical trials and the lack of in-house laboratory capacity are impeding the growth of the market. Also, some other factors such as the structural changes associated with the employment in the industry, fluctuating exchange rate and freight charges, etc. are acting as a headwind that is inhibiting the growth of the market, mostly in the developing regions.

Nevertheless, improving economic conditions globally, are expected to support market growth, allowing increasing funding for the R&D activities for new drug discovery.

Key Players:

Key players leading the global small molecule API market are Allergan Plc, Albemarle Corporation, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd, Cambrex Corporation, Glaxosmithkline Plc, Merck Sharp & Dohme Corp., Lonza, Mylan N.V., Pfizer Inc., Novartis AG, Siegfried AG, Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. among others.

Small Molecule API Market – Segmentations

MRFR has segmented the report into four key dynamics for an easy grasp;

By Types: Synthetic/Chemical API and Biological API among others.

By Application: Cardiovascular, Oncology, Diabetes, and Immunological Disorders among others.

By Manufacturing Method: In-house and Contract.

By Region: Asia Pacific, North America, Europe, and Rest-of-the-World (RoW).

Small Molecule API Market – Regional Analysis

Globally, the North American region accounts for the leading market for the small molecule API securing around 38% of market share. The market is expected to reach USD 106.3 BN by 2027. Factors such as the growing activities of development and manufacturing process by pharmaceutical and biotechnology companies, the presence of a well-proliferated healthcare sector, and huge patient pool, are substantiating the growth of the market.

The European small molecule API market accounts for the second-largest market, followed by the Asia Pacific region closely. Factors fostering the growth of the market include the presence of promising players mainly in the UK, Germany, and Switzerland.

Additionally, factors such as the presence of a well-proliferated healthcare sector, increasing funding for research activities from the public & private organizations, substantial patient population, and the resurging healthcare expenditures are boosting the growth of the regional market.

The Asia Pacific region is evolving as a promising market for small molecule API owing to the substantial investments by Asian CDMOs that are resultantly sufficing the exponential progress of the regional market. Moreover, the factors such as the availability of cost-competitive, skilled labor force are propelling the market growth in this region, attracting foreign investors.

Ever-increasing patient population, along with the continually improving economic conditions are providing impetus to the growth of the regional market. The APAC small molecule API market is anticipated to register a CAGR of 7.3% during the forecast period.

Small Molecule API Market – Competitive Landscape

The highly competitive, small molecule API market appears to be widely expanded and fragmented characterized by the several small and large-scale companies operating the market.  These companies compete against each other based on pricing and an array of services.

The competitive strength of these companies is dependent on factors such as service pricing, service precision, versatility, and reliability. The competition is expected to intensify due to the great innovations.

Industry/Innovation/Related News:

January 02, 2019 –– Cambrex Corporation (US), a leading manufacturer of small molecule innovator and generic APIs announced the completion of the acquisition process of Avista Pharma Solutions (UK), a contract development, manufacturing, and testing organization (CDMO).

Avista had recently (Sep. 2018) expanded its service offerings in New England alongside the Analytical Chemistry Suite and office in New Boston Metro area. The acquisition further strengthens Cambrex’s position as the leading, fully integrated small molecule contract development and manufacturing organization (CDMO) in the entire drug lifecycle, across the US & UK.

Browse Complete 85 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India